Dipyridamole: Wikis


Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.


From Wikipedia, the free encyclopedia

Systematic (IUPAC) name
2,2',2'',2'''-(4,8-di(piperidin-1-yl)pyrimido[5,4- d]pyrimidine-2,6-diyl)bis(azanetriyl)tetraethanol
CAS number 58-32-2
ATC code B01AC07
PubChem 3108
DrugBank APRD00360
ChemSpider 2997
Chemical data
Formula C 24H40N8O4  
Mol. mass 504.626 g/mol
SMILES eMolecules & PubChem
Pharmacokinetic data
Bioavailability  ?
Protein binding 99%
Metabolism Hepatic
Half life Alpha (40 mins), Beta (10 Hours)
Excretion  ?
Therapeutic considerations
Pregnancy cat. B
Legal status
Routes PO, IV
 Yes check.svgY(what is this?)  (verify)

Dipyridamole (also known commercially by Persantine) is a drug that inhibits thrombus formation[1] when given chronically and causes vasodilation when given at high doses over short time.


Mechanism and effects

  • Inhibits Thromboxane synthase, therefore lowering the levels of TXA2 and thus stops the effects of TXA2 (platelet aggregation, bronchioconstriction and vasoconstriction).
  • It inhibits the cellular reuptake of adenosine into platelets, red blood cells and endothelial cells leading to increased extracellular concentrations of adenosine.
  • It also inhibits the enzyme adenosine deaminase which normally breaks down adenosine into inosine. This inhibition leads to further increased levels of extracellular adenosine.
  • Dipyridamole also inhibits the phosphodiesterase enzymes which normally break down cAMP (increasing cellular cAMP levels and blocking the platelet response to ADP) and/or cGMP (resulting in added benefit when given together with NO or statins).


  • Dipyridamole has been shown to lower pulmonary hypertension without significant drop of systemic blood pressure
  • Dipyridamole inhibits formation of pro-inflammatory cytokines (MCP-1, MMP-9) in vitro and results in reduction of hsCRP in patients.
  • Dipyridamole inhibits proliferation of smooth muscle cells in vivo and has shown to prevent AV-shunt failure in dialysis patients.
  • Dipyridamole increases release of t-PA from brain microvascular endothelial cells
  • Dipyridamole treatment in vivo results in increase of 13 - HODE and decrease of 12 - HETE in the subendothelial matrix (SEM) and reduced thrombogenicity of the SEM.
  • Dipyridamole pretreatment reduced reperfusion injury in volunteers.
  • Dipyridamole treatment has shown to increase myocardial perfusion and left ventricular function in patients with ischemic cardiomyopathy.
  • Dipyridamole treatment resulted in reduction of the number of thrombin and PECAM-1 receptors on platelets in stroke patients.
  • cAMP impairs platelet aggregation and also causes arteriolar smooth muscle relaxation. Chronic therapy did not show significant drop of systemic blood pressure.
  • Dipyridamole inhibits the replication of mengovirus RNA.[2]

Use in individuals with a history of stroke

Modified release dipyridamole is used in conjunction with aspirin (under the trade names Aggrenox in the USA or Asasantin Retard in the UK) in the secondary prevention of stroke and transient ischaemic attack. Dipyridamole absorption is pH-dependent and concomitant treatment with gastric acid suppressors (such as a proton pump inhibitor) will inhibit uptake significantly.[3] This practice was now confirmed by the ESPRIT trial.[4]

It is not, however, licensed as monotherapy for stroke prophylaxis, although a Cochrane Review has suggested that dipyridamole may reduce the risk of further vascular events in patients presenting after cerebral ischaemia. [5]

A triple therapy of aspirin, clopidogrel and dipyridamole has been investigated, but this combination led to an increase in adverse bleeding events.[6]

  • Via the mechanisms mentioned above, when given as 3 to 5 min infusion it rapidly increases the local concentration of adenosine in the coronary circulation which causes vasodilation.
  • Vasodilation occurs in healthy arteries, whereas stenosed arteries remain narrowed. This creates a "steal" phenomenon where the coronary blood supply will increase to the dilated healthy vessels compared to the stenosed arteries which can then be detected by clinical symptoms of chest pain, electrocardiogram and echocardiography when it causes ischemia.
  • Flow heterogeneity (a necessary precursor to ischemia) can be detected with gamma cameras and SPECT using nuclear imaging agents such as Thallium-201 and Tc99m-Sestamibi. However relative differences in perfusion not necessarily imply absolute decrease in blood supply in the tissue supplied by a stenosed artery.

Other uses of dipyridamole

Dipyridamole also has non-medicinal uses in a laboratory context, such as the inhibition of cardiovirus growth in cell culture.


Classification and external resources
ICD-10 T46.3
ICD-9 972.4

Dipyridamole overdose can be treated with aminophylline[7] and reverses its hemodynamic effects (vasodilation). Symptomatic treatment is recommended, possibly including a vasopressor drug. Gastric lavage should be considered. Administration of xanthine derivatives (e.g., aminophylline) may reverse the hemodynamic effects of dipyridamole overdose. Since dipyridamole is highly protein bound, dialysis is not likely to be of benefit.


  1. ^ Dipyridamole at Dorland's Medical Dictionary
  2. ^ Dipyridamole in the laboratory: Fata-Hartley, Cori L.; Ann C. Palmenberg. "Dipyridamole reversibly inhibits mengovirus RNA replication". doi:10.1128/JVI.79.17.11062-11070.2005. http://jvi.asm.org/cgi/content/full/79/17/11062?view=long&pmid=16103157. Retrieved 2007-02-13.  
  3. ^ Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. (1996). "European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke". J Neurol Sci 143 (1-2): 1–13. doi:10.1016/S0022-510X(96)00308-5. PMID 8981292.  
  4. ^ Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A (May 2006). "Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial". Lancet 367 (9523): 1665–73. doi:10.1016/S0140-6736(06)68734-5. PMID 16714187. http://linkinghub.elsevier.com/retrieve/pii/S0140-6736(06)68734-5.  
  5. ^ De Schryver ELLM, Algra A, van Gijn J. (2007). "Dipyridamole for preventing stroke and other vascular events in patients with vascular disease.". Cochrane Database of Systematic Reviews 2007 (2): CD001820. doi:10.1002/14651858.CD001820.pub3. http://www.cochrane.org/reviews/en/ab001820.html.  
  6. ^ Sprigg N, Gray LJ, England T, et al. (2008). "A randomised controlled trial of triple antiplatelet therapy (aspirin, clopidogrel and dipyridamole) in the secondary prevention of stroke: safety, tolerability and feasibility". PLoS ONE 3 (8): e2852. doi:10.1371/journal.pone.0002852. PMID 18682741. PMC 2481397. http://www.plosone.org/article/info:doi/10.1371/journal.pone.0002852.  
  7. ^ Aggrenox. RxList.com. URL: http://www.rxlist.com/cgi/generic/aggrenox_od.htm. Accessed on: May 1, 2007.

Got something to say? Make a comment.
Your name
Your email address